News & Press

[PR Newswire]Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

BASEL, Switzerland, March 26, 2025

[PR Newswire]OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

BASEL, Switzerland, March 25, 2025

[PR Newswire]OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

SEOUL, South Korea, Feb. 14, 2025